Clinigen Group, United Therapeutics sales and marketing update

The U.K.’s NICE issued draft guidance recommending against Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in combination with GM-CSF, IL-2 and isotretinoin in patients ages 12 months to 17 years -- its approved indication. The agency said the chimeric mAb targeting GD2 was not a cost-effective use of NHS resources. United estimated the total cost of a complete course of Unituxin in combination with GM-CSF, IL-2 and isotretinoin to be L135,404 ($205,855). NICE said when it applied its preferred assumptions, the incremental cost-effectiveness ratio (ICER) was L139,600 ($212,234) per quality-adjusted life year (QALY) gained. ...